Method for Producing Significant Amounts of B19 Virus for Development of Killed or Attenuated Vaccines

Human parvovirus B19 (B19) is a common infection of children and adults and is the cause of fifth disease. B19 selectively infects erythroid progenitor cells of bone marrow, fetal liver and a small number of specialized cell lines. These specific cell lines demonstrate limited infectibility and commonly produce little or no virus following initial inoculation with B19. Current methods for producing infectious B19 require phlebotomy of infrequently available infected donors. The available technology describes a method of producing pure populations of human erythroid progenitor cells that are fully permissive to B19 infection. The ability to efficiently generate significant amounts of infectious B19V in cells is useful for the development of killed or attenuated vaccines, therapeutics and efficient diagnostic tools for prevention and treatment of B19V.

Potential Commercial Applications:		Competitive Advantages:
Human parvovirus B19 diagnostic Vaccine manufacture Research and development of anti-parvovirus agents		Method produces pure populations of human erythroid progenitor cells that are fully permissive of B19 infection

Development Stage:

• Pre-clinical
• In vitro data available

Inventors:

Susan Wong (NHLBI)  ➽ more inventions...

Neal Young (NHLBI)  ➽ more inventions...


Intellectual Property:
US Application No. 12/301,960
PCT Application No. PCT/US2007/012645
US Application No. 60/808,904

Publications:
Giarratana MC, et al. PMID 15619619
Freyssinier JM, et al. PMID 10519992

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-188-2006-0
Updated: Apr 21, 2016